Audited results for year ended 31 December 2025

AI SummaryClose X

Shield Therapeutics plc reported audited results for the year ended 31 December 2025, with group net revenues and other income reaching $49.7 million, driven by a 56% increase in ACCRUFeR® net revenues to $45.8 million, making it the number one branded prescription oral iron in the US. The company achieved positive cash flow in Q4 2025 and anticipates an operating profit in 2026, with losses for the year reduced to $17.7 million from $27.2 million in 2024. Significant progress was made in expanding global patient access to ferric maltol, including FDA approval for adolescent use and launches in Canada and regulatory approval in South Korea, while debt facilities were amended to provide increased flexibility.

Disclaimer*

UK 100

Latest directors dealings